acarbose
acarbose
Overview
Acarbose is an orally administered antidiabetic drug used primarily to reduce postprandial hyperglycemia. It acts as an inhibitor of intestinal carbohydrate-digesting enzymes, especially α-glucosidase, and is also commonly used as a reference inhibitor in studies of α-amylase and related carbohydrate-hydrolyzing targets. By slowing the breakdown of complex carbohydrates into absorbable monosaccharides, acarbose reduces the rate at which glucose enters the bloodstream after meals.
In biomedical research, acarbose is frequently used as a benchmark compound for evaluating new α-glucosidase inhibitors, antidiabetic natural products, and synthetic small molecules. In the recent studies summarized here, it served both as a comparator drug and as a target-related reference in assays examining enzyme inhibition, docking, and postprandial glucose control. The surrounding research context also links acarbose to broader metabolic and functional-food investigations involving alpha-glucosidase, amylase alpha 1C, obesity, and hyperinsulinemic T2D patients.
Focus of Latest Publications
Recent publications have continued to use acarbose as a reference standard for evaluating new antidiabetic approaches, most often in studies centered on intestinal carbohydrate-digesting enzymes and postprandial glycemic control. Several reports compared experimental compounds or extracts against acarbose in alpha-glucosidase or alpha-amylase inhibition assays, reflecting its role as a benchmark therapy for reducing postprandial glucose excursions. In these studies, acarbose was used alongside in vitro enzyme assays, molecular docking, and in some cases in vivo glucose-loading models to contextualize the potency of newly identified candidates.
Multiple natural-product studies reported activity approaching or exceeding that of acarbose. Chia seed methanolic extract produced a glycemic curve comparable to acarbose in normoglycemic Wistar rats after oral sucrose challenge, while rosmarinic acid and its hexoside showed docking affinities toward alpha-glucosidase targets close to those of acarbose. In Garcinia nujiangensis, one biphenyl derivative was described as approximately 7 times stronger than acarbose as an alpha-glucosidase inhibitor. Similarly, Fagonia cretica extract showed alpha-amylase inhibition that was weaker than acarbose, but docking highlighted quercetin, luteolin, and catechin as strong binders to antidiabetic targets. Pomegranate-husk-derived ZnO nanoparticles also inhibited alpha-amylase and pancreatic lipase at levels comparable to standard drugs such as acarbose and orlistat.
Synthetic and peptide-based studies likewise used acarbose as the comparator for improved enzyme inhibition. A modified food-derived peptide, YAPSW, inhibited alpha-glucosidase more strongly than both its parent peptide and acarbose, and also improved insulin resistance-related signaling. Thiazole-hydrazine-isoindole hybrids, especially TR6, showed markedly greater alpha-glucosidase inhibition than acarbose and favorable in silico drug-likeness. Methyl-glycosyl furanose-based sulfonium inhibitors displayed potent maltase, sucrase, and isomaltase inhibition, with several compounds matching or surpassing acarbose; notably, acarbose was reported to be almost inactive against isomaltase in that study. In vivo, LY-23 reduced postprandial blood glucose in mice after maltose or sucrose loading with efficacy comparable to voglibose and acarbose.
Other publications reinforced acarbose’s role as a comparator in broader antidiabetic screening. N-propylcarbazole-1,3-thiazole hybrid 5k outperformed acarbose in alpha-glucosidase inhibition and reduced postprandial glucose in zebrafish with comparable efficacy to acarbose. Pyrrole-based imidazothiazole derivatives also showed stronger alpha-amylase and alpha-glucosidase inhibition than acarbose, with compound 8 emerging as a leading candidate. Across these studies, acarbose served as the principal reference for gauging enzyme-inhibitory potency, helping position new natural, synthetic, and nanomaterial-based candidates for further development in glycemic management.